|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG005702305 |
003 |
DE-627 |
005 |
20230629100633.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2023 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG005702305
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2017-004021-33-GB
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)ANB019-002
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)NCT03619902
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a To Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis
|b A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis - ANB019-002 - Generalized Pustular Psoriasis
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 20-12-2017, Last updated: 2023-06-29
|
650 |
|
4 |
|a Medical Condition: Generalized Pustular Psoriasis (GPP) MedDRA version: 21.0Level: LLTClassification code 10037159Term: Psoriasis pustularSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 2
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 21. Juni
|
773 |
1 |
8 |
|g year:2023
|g day:21
|g month:06
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004021-33
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 21
|c 06
|